Products and services will be offered initially to customers in the United States and Canada. Global expansion is expected to start by the end of the year. Unisyn’s Diagnostic Imaging Field Services business will operate independently under a new name.

“The combination of Unisyn’s repair expertise and GE’s scale will provide value by meeting customers’ needs with a fast, cost effective and reliable probe repair solution,” said Mike Swinford, President and CEO of Global Services for GE Healthcare. “We see this as a tremendous opportunity to further grow our Ultrasound and Services footprint globally and look forward to providing our customers a cost effective solution at every step of the Ultrasound product lifecycle.”

Ultrasound customers around the world are challenged as they struggle to manage their broad ultrasound fleet of probes. They seek low cost, high quality solutions that can increase their uptime and reduce repeated failures.

Unisyn is uniquely positioned to test and evaluate ultrasound probe failures with its proprietary FirstCall™ probe-testing device. This patented technology enables Unisyn to diagnose, repair, and thoroughly test each and every probe before shipment back to the customer. FirstCall provides objective measures of probe performance through testing the acoustic and electrical properties of ultrasound probes.

“This transaction makes great sense for our stockholders, our employees and most importantly our customers,” said Jeff Soinski, CEO of Unisyn Medical Technologies. “Our ultimate goal at Unisyn is to deliver value for our customers and together with GE our transactional business is positioned to do this better than ever before. Through this acquisition, GE Healthcare will now be able to offer customers a complete probe repair solution spanning across multiple vendor platforms as well as a broad portfolio of on-demand offerings to meet customers’ unique needs.”

A new test for cervical cancer was found to detect all of the cancers in a randomised clinical screening trial of 15,744 women, outperforming both the current Pap smear and human papillomavirus (HPV) test at a reduced cost, according to a study led by Queen Mary University of London.